My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 113

    1.

    Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes.

    Sommeijer DW, MacGillavry MR, Meijers JC, Van Zanten AP, Reitsma PH, Ten Cate H.

    Diabetes Care. 2004 Feb;27(2):468-73.PMID: 14747230 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

    Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators.

    JAMA. 2001 Jul 4;286(1):64-70.PMID: 11434828 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.

    Li JJ, Li YS, Chu JM, Zhang CY, Wang Y, Huang Y, Chen J, Yuan JQ, Huang YL.

    Clin Chim Acta. 2006 Apr;366(1-2):269-73. Epub 2005 Dec 15.PMID: 16343471 [PubMed - indexed for MEDLINE]Related articles

    4.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    5.

    Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.

    Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators.

    Circulation. 2004 Aug 31;110(9):1103-7. Epub 2004 Aug 16.PMID: 15313950 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes.

    Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB.

    Diabetes Care. 2004 Jul;27(7):1680-7.PMID: 15220246 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.

    Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL.

    Clin Ther. 2007 Jan;29(1):74-83.PMID: 17379048 [PubMed - indexed for MEDLINE]Related articles

    8.

    The effect of multi-factorial intervention on plasma von Willebrand factor, soluble E-selectin and tissue factor in diabetes mellitus: implications for atherosclerotic vascular disease.

    Lim HS, Chong AY, Freestone B, Blann AD, Lip GY.

    Diabet Med. 2005 Mar;22(3):249-55.PMID: 15717870 [PubMed - indexed for MEDLINE]Related articles

    9.

    Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.

    Chappuis B, Braun M, Stettler C, Allemann S, Diem P, Lumb PJ, Wierzbicki AS, James R, Christ ER.

    Diabetes Metab Res Rev. 2007 Jul;23(5):392-9.PMID: 17211855 [PubMed - indexed for MEDLINE]Related articles

    10.

    Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?

    Ng TW, Watts GF, Stuckey BG, Ching HL, Chan DC, Uchida Y, Sakai N, Yamashita S, Martins IJ, Redgrave TG, Barrett PH.

    Clin Endocrinol (Oxf). 2005 Dec;63(6):650-6.PMID: 16343099 [PubMed - indexed for MEDLINE]Related articles

    11.

    Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

    Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

    Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    13.

    Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response.

    Di Garbo V, Bono M, Di Raimondo D, De Simone R, Raneli G, Avellone G.

    Eur J Clin Pharmacol. 2000 Jul;56(4):277-84.PMID: 10954339 [PubMed - indexed for MEDLINE]Related articles

    14.

    Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

    Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N.

    Atherosclerosis. 1996 May;122(2):225-33.PMID: 8769685 [PubMed - indexed for MEDLINE]Related articles

    15.

    The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study.

    Sakamoto K, Sakamoto T, Ogawa H; Kumamoto Joint Research on Hypercholesterolemia Investigators.

    Clin Ther. 2006 Jul;28(7):1012-21.PMID: 16990079 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.

    De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD.

    J Intern Med. 2005 Jan;257(1):100-9.PMID: 15606381 [PubMed - indexed for MEDLINE]Related articles

    17.

    Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia.

    Lee WJ, Lee WL, Tang YJ, Liang KW, Chien YH, Tsou SS, Sheu WH.

    Clin Chim Acta. 2008 Apr;390(1-2):49-55. Epub 2007 Dec 23.PMID: 18201563 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids.

    Shinn AH, Carr-Lopez SM, Smith JW, Elledge EA, Smith TJ.

    Curr Med Res Opin. 2005 Feb;21(2):207-14.PMID: 15801991 [PubMed - indexed for MEDLINE]Related articles

    19.

    Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks.

    Solheim S, Seljeflot I, Arnesen H, Eritsland J, Eikvar L.

    Atherosclerosis. 2001 Aug;157(2):411-5.PMID: 11472741 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effects of long-term pravastatin treatment on serum and urinary monocyte chemoattractant protein-1 levels and renal function in type 2 diabetic patients with normoalbuminuria.

    Fujita H, Koshimura J, Sato T, Miura T, Sasaki H, Morii T, Narita T, Kakei M, Ito S, Yamada Y.

    Ren Fail. 2007;29(7):791-6.PMID: 17994445 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity